Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities Meeting Abstract
| Authors: | Boussi, L.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Aguirre, L. E.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; DeAngelo, D. J.; Stone, R. M.; Luskin, M. R.; Garcia, J. S.; Winer, E. S.; Chen, E.; Wadleigh, M.; Ling, K.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Shimony, S. O.; Stahl, M. |
| Abstract Title: | Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities |
| Meeting Title: | 66th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 144 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Dec 7-10 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2024-11-05 |
| Start Page: | 4281 |
| End Page: | 4283 |
| Language: | English |
| ACCESSION: | WOS:001411190600015 |
| DOI: | 10.1182/blood-2024-204467 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
